Ulka Nitin Vaishampayan, MBBS, discusses the intent of the phase 3 PROBE trial in advanced renal cell carcinoma.
Ulka Nitin Vaishampayan, MBBS, director, Phase I Program, Rogel Cancer Center, Michigan Medicine, professor of internal medicine, University of Michigan, discusses the intent of the phase 3 PROBE trial (NCT04510597) in advanced renal cell carcinoma (RCC).
The PROBE trial builds off the phase 3 CARMENA trial (NCT00930033), which reported interim results in 2018, Vaishampayan says. The CARMENA trial investigated whether the addition of cytoreductive nephrectomy to targeted therapy affected overall outcomes in patients with metastatic RCC. CARMENA determined that treatment with sunitinib (Sutent) alone was noninferior to cytoreductive nephrectomy followed by sunitinib in terms of overall survival.
Because advanced RCC treatment standards have shifted since the CARMENA trial, the PROBE trial seeks to determine whether cytoreductive nephrectomy can influence patient outcomes when combined with an immunotherapy-based combination. Preclinical data indicate immunotherapy-based combination therapy increases the chances of response, Vaishampayan concludes.